^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Prostate Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    napabucasin (BBI608) (STAT3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial)

    Published date:
    07/21/2020
    Excerpt:
    Napabucasin with pembrolizumab showed anti-tumor activity with acceptable toxicities for MSS mCRC patients as well as MSI-H mCRC...
    DOI:
    10.1158/1078-0432.CCR-20-1803